Edition:
India

Profile: ADMA Biologics Inc (ADMA.OQ)

ADMA.OQ on NASDAQ Stock Exchange Capital Market

2.69USD
12:13am IST
Change (% chg)

$0.06 (+2.28%)
Prev Close
$2.63
Open
$2.64
Day's High
$2.70
Day's Low
$2.60
Volume
7,639
Avg. Vol
30,111
52-wk High
$5.74
52-wk Low
$2.02

ADMA Biologics, Inc., incorporated on June 2, 2006, is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. The Company's segments include Plasma Collection Centers, Research and Development, and Corporate. The Plasma Collection Centers segment includes the Company's operations in Georgia. The Research and Development segment includes the Company's plasma development operations in New Jersey. The Company's targeted patient populations include immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. The Company's lead product candidate, RI-002, is intended for the treatment of primary immune deficiency disease (PIDD) and has completed a pivotal Phase III clinical study.

The Company's intravenous immunoglobulin (IVIG) product candidate, RI-002, contains polyclonal antibodies against various infectious agents. RI-002 is an injectable immune globulin derived from human plasma, supplemented with levels of naturally occurring polyclonal antibodies (streptococcus pneumoniae, H. influenza type B, cytomegalovirus (CMV), measles and tetanus), as well as levels of antibodies targeted to Respiratory Syncytial Virus (RSV). Its microneutralization assay allows the Company to regulate RI-002's potency by identifying and isolating hyperimmune donor plasma with RSV antibodies, thereby allowing it to differentiate its immune globulin. RI-002's predecessor product candidate, RI-001, is the subject of a Phase II randomized, double-blind, placebo-controlled human clinical trial in RSV-infected, immune-compromised patients. RI-002 is a formulation of its prior product candidate RI-001.

The Company competes with Baxter HealthCare Corporation, CSL Behring, Grifols Biologicals, Octapharma and Biotest.

Company Address

ADMA Biologics Inc

C/O Adma Biologics
Inc., 465 State Route 17
RAMSEY   NJ   07446
P: +1201.4785552
F: +1201.4785553

Company Web Links